Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
NASDAQ:HOTH

Hoth Therapeutics 8/9/2024 Earnings Report

Hoth Therapeutics logo
$0.69 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$0.67 -0.02 (-3.19%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Hoth Therapeutics EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Hoth Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hoth Therapeutics Announcement Details

Quarter
Date
8/9/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Hoth Therapeutics' next earnings date is estimated for Wednesday, June 3, 2026, based on past reporting schedules.

Conference Call Resources

Hoth Therapeutics Earnings Headlines

Hoth Therapeutics, Inc.: AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of ...
May 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68536475-hoth-therapeutics-inc-ai-chip-energy-efficiency-hoth-therapeutics-restructures-as-rocket-one-inc-to-enter-the-ai-semiconductor-infrastructure-mar-008.htm
Hoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH)
May 20, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/hoth-therapeutics-shares-slide-after-shift-toward-ai-semiconductor-strategy-hoth/ar-AA23zmNS
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
May 26 at 1:00 AM  |  Porter & Company (Ad)
AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture
May 19, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ai-chip-energy-efficiency-hoth-therapeutics-restructures-as-rocket-one-inc-to-enter-the-ai-semiconductor-infrastructure-market-with-acquisition-of-exclusive-rights-to-next-generation-ai-semiconductor-acceleration-technology-buil-302776054.html
Hoth Therapeutics Launches Rocket One Space Subsidiary Initiative
May 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/hoth-therapeutics-launches-rocket-one-space-subsidiary-initiative?utm_source=marketbeat.com&utm_medium=referral
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
May 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hoth-therapeutics-secures-european-authorization-in-spain-for-ht-001-phase-2a-trial-as-interim-data-show-strong-efficacy-in-cancer-patients-302762976.html
See More Hoth Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hoth Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hoth Therapeutics and other key companies, straight to your email.

About Hoth Therapeutics

Hoth Therapeutics (NASDAQ:HOTH) is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis. The company holds exclusive worldwide licenses for a range of small molecules and biological compounds sourced from leading academic institutions and research organizations. By advancing these assets through preclinical studies and early-stage clinical trials, Hoth aims to validate therapeutic potential and move products toward regulatory milestones and eventual commercialization.

Founded in 2018 and headquartered in New York, Hoth Therapeutics operates through strategic collaborations with universities, entrepreneurial biotech firms and contract research organizations. The company’s management team brings expertise in drug development, regulatory affairs and commercial strategy, positioning Hoth to navigate the complexities of clinical advancement and market entry. With a focus on specialized delivery technologies and precision formulations, Hoth seeks to address unmet medical needs and deliver innovative treatment options to patients worldwide.

View Hoth Therapeutics Profile
Earnings Tools